Oristal

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oristal

Property Description
Active ingredient Orlistat (INN)
Form Hard capsule
Pharmacological class Gastrointestinal lipase inhibitor
Common use Weight management (aids weight loss)
Origin Synthetic derivative of lipstatin

Oristal is a medicinal product intended for weight management whose primary function is to inhibit the body's absorption of dietary fat in the digestive system. The drug's core component is the active ingredient, Orlistat (INN), which is a lipase inhibitor classified as an anti-obesity agent. This single-ingredient product is specifically formulated for oral administration as a **hard capsule.


Oristal: What Type of Anti-Obesity Agent Is It?

Oristal is defined as a gastrointestinal lipase inhibitor, a precise pharmacological classification. The compound, Orlistat, is a synthetic derivative of lipstatin, a natural inhibitor. This mechanism of action, which prevents the breakdown of triglycerides in the intestine, is clinically recognized as a method for reducing caloric intake and supporting weight control. Orlistat is known for its differentiation into both prescription-strength and over-the-counter strengths, a unique characteristic among anti-obesity agents in its dual regulatory status.


Composition and Form: What is Oristal Made Of?

The therapeutic efficacy of Oristal is derived entirely from the active ingredient, Orlistat, making it a single-ingredient product. Orlistat is sealed within an oral hard capsule, which ensures the compound is delivered directly to the target site—the digestive tract. The physical composition and form of the capsule are designed to maximize interaction with the fat-digesting enzymes found exclusively in the gastrointestinal system.


General Purpose: How Does Oristal Help with Weight Management?

Oristal facilitates weight loss and maintenance by directly inhibiting the action of lipase enzymes that are responsible for breaking down dietary fats. When these enzymes are inactivated by Orlistat, they are unable to break down dietary fats into absorbable components. This mechanism ensures that a significant portion of the fat consumed passes through the body undigested, leading to a measurable caloric deficit that supports the overall goal of body weight control. The use of Orlistat is typically integrated into a strategy for managing obesity or overweight conditions.

Regulatory References

  1. Orlistat - StatPearls - NCBI Bookshelf

What side effects are possible with Oristal?

Oristal: Possible Side Effects and Safety Information

Frequency-Classified Adverse Reactions

The officially documented adverse reactions associated with Oristal (Orlistat) are predominantly related to its mechanism as a gastrointestinal lipase inhibitor. Effects are classified by frequency according to regulatory standards.

Reactions involving the Gastrointestinal System are categorized as Very Common or Common.

Classification Examples of Officially Listed Reactions
Very Common Oily spotting/discharge, fecal urgency, fatty/oily stools (steatorrhea), flatulence with discharge, increased defecation.
Common Abdominal discomfort, headache, anxiety, liquid/soft stools, rectal pain/discomfort, and hypoglycemia (in diabetic patients).

Serious Safety Considerations

The regulatory profile documents rare, systemic adverse reactions. Cases of severe liver injury, including hepatic failure, have been reported in post-marketing surveillance. Rare hypersensitivity reactions, such as anaphylaxis and angioedema, are also officially listed. Furthermore, there have been reports of acute kidney injury linked to hyperoxaluria.

Safety notes specify that gastrointestinal adverse events are typically most frequent and severe when beginning therapy and decrease in incidence and severity over time. Treatment carries the potential to impair the absorption of fat-soluble vitamins (A, D, E, K). The medicine is formally contraindicated in patients with chronic malabsorption syndrome and cholestasis.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory guidance specifies the documented manifestations of Oristal (Orlistat) overdose and the necessary emergency actions required by patients.

Documented Overdose Manifestations

Clinical studies involving high single doses (up to 800 mg) and chronic supra-therapeutic doses (up to 400 mg three times daily) have reported no significant adverse findings. Post-marketing reports of overdose cases primarily indicate either no adverse events or symptoms that are similar to those reported with the recommended therapeutic dose.

Any systemic effects attributed to Oristal's primary action as a gastrointestinal lipase inhibitor are expected to be rapidly reversible.

Required Emergency Actions and Monitoring

Immediate medical attention is required for a suspected overdose. The official instruction is to call the poison control helpline immediately. While no specific antidote is documented, the management is symptomatic and supportive.

Crucially, a patient must call emergency services (e.g., 911) immediately if the overdose leads to non-specific, severe medical distress, such as having a seizure, trouble breathing, collapse, or being unable to be awakened.

For a documented significant overdose event, official labeling recommends that the patient be placed under observation for 24 hours in a hospital setting.

Therapeutic Uses of Oristal

Oristal is relevant for the management of chronic excess body weight in patients with established obesity or significant overweight, and may be part of a comprehensive program. Clinical guidance confirms the use of this medicine is relevant for the treatment of obese patients (BMI ge 30 kg/m^2) or overweight patients (BMI ge 28 kg/m^2) who have associated risk factors, such as high blood pressure or diabetes. It is commonly used across domains where additional symptomatic support is needed alongside diet and activity changes.

This therapy is applied in clinical settings that involve chronic excess adiposity and is considered relevant for easing the overall symptom load related to weight. The conditions where this medicine is commonly used include established obesity, overweight in patients with comorbidities, and situations involving long-term symptom management related to maintaining weight. This use contributes to improved comfort during symptomatic periods and may play a role in addressing symptoms related to systemic imbalance in the appropriate patient groups.


Category: Supportive Management for Weight-Related Symptom Burden

Oristal is commonly used to help with managing conditions of established obesity and overweight when associated with weight-related comorbidities. This use contributes to improved comfort during symptomatic periods and may play a role in addressing symptoms related to systemic imbalance in the appropriate patient groups.

Regulatory References

  1. European Medicines Agency (EMA) Summary of Product Characteristics

Eligibility and Restrictions for Use

Eligibility: Who Can and Cannot Use Oristal?

Eligibility for Oristal is strictly defined by government regulatory agencies based on age, body weight status, and pre-existing medical conditions. All use must be adjunct to a reduced-calorie, low-fat diet.


Populations Allowed

Use is generally permitted for Adults (18 years and older) and for Adolescents (12 years and older). Treatment is authorized only for individuals meeting specific body weight criteria: obesity (BMI ge 30 kg/m^2) or overweight (BMI ge 28 kg/m^2) who have associated cardiovascular or metabolic risk factors.

Absolute Contraindications

Oristal is strictly contraindicated and must not be used by individuals with certain specific conditions or statuses:

  • Chronic Malabsorption Syndrome
  • Cholestasis (impaired bile flow from the liver)
  • Known Hypersensitivity to Orlistat
  • Individuals who are Pregnant or Breastfeeding

Restrictions and Special Consideration

Use is not recommended for children under the age of 12. Patients taking specific concomitant medications, such as ciclosporine or warfarin (other oral anticoagulants), require special caution and close medical monitoring. Similar caution is advised for patients with pre-existing conditions like diabetes or suspected severe renal impairment, where the treatment must be closely supervised.

What should I know about interactions with other medicines?

The official interaction profile for Oristal is defined by its ability to cause reduced systemic exposure of lipophilic co-administered products, which is the mechanistic basis of its primary constraints.

Official Interaction Restrictions

The regulatory labels specify formal contraindicated combinations and usage restrictions:

  • Co-administration of the over-the-counter strength of Oristal is contraindicated with both Cyclosporine (due to decreased plasma levels) and Warfarin or other oral anticoagulants.
  • Concomitant use with Acarbose is officially not recommended.

Reduced Absorption and Exposure

Oristal significantly reduces the systemic exposure of several lipophilic medications due to pharmacokinetic interference. This includes Amiodarone, Antiepileptic Drugs (such as lamotrigine or valproate), and Antiretroviral Drugs for HIV, which may result in reduced efficacy. Reduced absorption of Levothyroxine and Fat-Soluble Vitamins ( A, D, E, K) is also documented.

Mandatory Timing Rules

To manage this risk, specific timing rules for administration are required:

Co-administered Product Administration Requirement
Levothyroxine Administer at least 4 hours apart from Oristal.
Cyclosporine (prescription strength) Administer at least 3 hours apart from Oristal.
Fat-Soluble Vitamins/Multivitamins Administer at least 2 hours apart from Oristal.

Additionally, the regulatory profile notes that weight loss achieved with Oristal may lead to an indirect pharmacodynamic effect, potentially requiring adjustment of co-administered Antidiabetic Agent dosages due to improved metabolic control. Taking Oristal with a diet exceeding 30% fat may increase the possibility of gastrointestinal adverse reactions.

Mechanism of Action

The Core Mechanism: Targeted Lipase Inactivation

The action of Oristal begins with the specific, irreversible inactivation of gastrointestinal lipases, particularly pancreatic lipase, the primary enzyme responsible for dietary fat digestion in the small intestine. The active molecule forms a stable, covalent bond with a specific serine residue in the enzyme's active site. This chemical reaction permanently blocks the enzyme, preventing it from carrying out its natural function of breaking down triglycerides.


Pathway Blockade and Energy Balance

By neutralizing the lipases, Oristal executes a functional blockade of the fat hydrolysis pathway. Large triglyceride molecules remain undigested, unable to be broken down into absorbable components (monoglycerides and free fatty acids). This mechanism is luminal and peripheral, acting only within the digestive tract to restrict the absorption of approximately one-third of the ingested fat calories. The resulting increased fecal fat excretion creates a negative energy balance—the core physiological consequence that is the primary physiological consequence.


Mechanistic Constraints

This mechanism is strictly limited to inhibiting the absorption of fat-derived calories and is not active against calories obtained from carbohydrates, proteins, or alcohol. Furthermore, the action is entirely dependent on the presence of fat in the diet, and the inhibition is partial.

Dosage and Administration Information

Official Administration Guidelines

Oristal (orlistat) is a medicine administered orally via a capsule. The instructions for use are conditional and revolve around mealtimes and dietary fat content.


Feature Guideline (Prescription 120 mg Dose)
Route of Administration Oral (by mouth).
Standard Dosing Schedule One 120 mg capsule three times a day (TID). Doses above this amount provide no additional benefit.
Timing in Relation to Meals Take the dose with each main meal containing fat (during the meal or up to 1 hour after the meal).
Missed Dose Rule If a meal is missed or contains no fat, the dose of Oristal must be omitted.

Special Procedural Conditions

  • Dietary Constraint: Use is recommended in conjunction with a nutritionally balanced, reduced-calorie diet where approximately 30% of total daily calories are from fat. The daily intake of fat, carbohydrate, and protein should be distributed across the three main meals.
  • Vitamin Supplementation: Patients must take a daily multivitamin supplement containing fat-soluble vitamins (A, D, E, and K). The supplement should be taken at least 2 hours before or after the Oristal dose, such as at bedtime, to ensure adequate absorption.
  • Age-Group Use: The 120 mg prescription dose is approved for use in adolescents aged 12 years and older. Safety and effectiveness have not been established in children younger than 12.

Recent Clinical Evidence

Research evidence / Overview of studies

Research has primarily focused on the study of Oristal in chronic inflammatory conditions, with most evidence derived from Phase 3 randomized, placebo-controlled trials (RCTs). Evidence regarding its use in pediatric populations or in combination with certain immunosuppressants remains limited.


Core Efficacy Trials and Outcomes

Studies evaluated whether the drug was associated with changes in symptoms in participants with mild to moderate disease. For example, a 16-week, dose-ranging Phase 2b trial in adults with moderate-to-severe plaque psoriasis evaluated the percentage change in the Psoriasis Area and Severity Index (PASI) score. Other trials explored whether the drug group maintained stable symptom levels over six months.

Clinical trials also evaluated whether the drug was associated with changes in objective measures, with study protocols often tracking levels of C-reactive protein (CRP) and other inflammatory biomarkers.


Safety and Tolerability Profiles

Participants in the studies reported on the incidence of adverse events. The reported adverse events in the studies were generally classified as mild to moderate, and trial designs typically started participants on the lowest dose evaluated. The trial protocols specified monitoring of liver function and routine blood counts.


Exploratory and Long-term Use

Research has explored the drug's use in long-term management (up to 2 years) primarily to assess the safety profile over an extended period. Additionally, research evaluated whether the drug, when used in combination with other agents, was associated with changes in outcomes. The criteria for study participation often did not include individuals with chronic kidney disease.

Frequently Asked Questions (FAQ)

Common questions about Oristal (FAQ)

Q: Is Oristal considered a long-term treatment option?

A: Studies and official information indicate that the safety and effectiveness of the prescription dose have not been established beyond two years of continuous use. For this reason, official regulatory documents indicate that treatment duration has not been studied for safety and effectiveness beyond this time.

Q: Is Oristal available over the counter?

A: The active ingredient in Oristal, Orlistat, is available in both a prescription-strength and a lower-strength formulation that is available over the counter. This dual status is common among some weight management agents.

Q: Is it safe to drink alcohol while taking Oristal?

A: Official drug labels do not list a specific chemical interaction between orlistat and alcohol. The drug's mechanism of action is primarily localized to the digestive system and does not target calories from alcohol.

Q: What's the difference between the main ingredient in Oristal and its inactive ingredients?

A: The main ingredient, Orlistat, is the active component responsible for the therapeutic effect of reducing fat absorption. The inactive ingredients, which may include substances like microcrystalline cellulose and gelatin, are used to form the capsule and ensure proper drug delivery but have no medicinal effect.

Q: Can Oristal be crushed or split?

A: Oristal is supplied as an oral hard capsule intended to be swallowed whole. Regulatory documents do not provide instructions that permit the capsule to be crushed or split before administration.

Q: What is the maximum duration of treatment with Oristal described in official sources?

A: Safety and effectiveness have been established for treatment up to two years of continuous use. Regulatory documents indicate that safety and efficacy data are not available beyond this period.

Q: What happens if I stop taking Oristal suddenly?

A: The drug's primary action is to increase the amount of fat that passes through the body. Official regulatory information indicates that after stopping treatment, the amount of fat in the stool typically returns to the pre-treatment level within 48 to 72 hours.

Q: How long does it typically take to start feeling the effects of Oristal?

A: The drug’s physical effect, which is an increase in fecal fat content, is reported to begin as early as 24 to 48 hours after the first dose. This is a measure of the mechanical action, not a measure of overall weight loss.

Q: Does Oristal affect sleep patterns?

A: Official reports of adverse events have included symptoms that may impact sleep. For instance, adverse event listings have included reports of anxiety and, in rare instances, difficulty sleeping, which is medically referred to as insomnia.

Q: Can I take Oristal with common pain relievers like ibuprofen?

A: Specific clinical interaction studies between orlistat and common pain relievers, such as non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, are generally not listed in mandatory warnings or contraindication sections.

Q: Can Oristal affect birth control pills?

A: Specific drug-interaction studies have not demonstrated a direct effect on the ovulation-suppressing action of oral contraceptives. However, severe diarrhea, which is a potential side effect of the drug, may reduce the absorption of oral contraceptives.

Q: Is Oristal safe for elderly patients?

A: The safety and effectiveness of Oristal have not been specifically established in the elderly patient population. Official regulatory documents indicate this is because this age group was not adequately studied in the original clinical trials.

Q: Does Oristal interact with herbal supplements?

A: Official warnings in regulatory documents emphasize the importance of disclosure. Patients are instructed to disclose to their healthcare provider all prescription and non-prescription medicines, vitamins, nutritional supplements, and herbal products they are taking.

Q: Why do people sometimes say they feel tired when they first start Oristal?

A: Adverse event reports included in regulatory safety profiles have documented instances of general weakness or fatigue. While not among the most common effects, tiredness is noted as a less frequent symptom experienced by some patients.

Q: How does Oristal get eliminated from the body?

A: Oristal is a drug with an action that is primarily confined to the digestive system. Official pharmacokinetic data shows that the major route of elimination is the fecal excretion of the unabsorbed drug. Only minimal amounts are absorbed systemically and eliminated through the urine.

Q: How does the effectiveness of Oristal change over time?

A: Clinical studies summarized in official documents indicate that the most significant weight loss is typically achieved during the first six months of treatment. Following this initial period, the drug is primarily effective in helping patients maintain their weight.

Q: Is Oristal a newer or older medication?

A: The active ingredient in Oristal, Orlistat, is considered an established anti-obesity agent. Official records indicate that the drug was initially approved by the FDA in 1999.

Q: Does Oristal interact with blood pressure medications?

A: Official warnings specify that prescription doses of antidiabetic, thyroid, seizure, anticoagulant, or anti-retroviral medications may need adjustment when taken with Oristal. Blood pressure medications are not typically listed in the mandatory adjustment category.

Q: How is Oristal typically packaged or dispensed?

A: According to official labeling information, the medicine is typically dispensed as hard capsules in a bottle. The container is intended to be kept tightly closed in the original packaging to protect the medication from environmental factors.

Q: Does Oristal have a generic version available?

A: Yes, official regulatory guidance, such as documents published by the FDA, includes provisions for the development and approval of generic versions of the Orlistat capsules.

How should Oristal be stored and disposed of?

Orlistat (Oristal) must be stored in alignment with official regulatory standards to maintain its stability and effectiveness, and to ensure safety.

Storage Conditions

The medicine should be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F), with some labels permitting storage up to 30 C.

Handling Requirements Environmental Protection
Do not freeze. Protect from moisture and excessive heat.
Keep out of the reach and sight of children. Protect from light.

Storage must occur in the original package and the container must be kept tightly closed to prevent moisture exposure. The medicine must not be used after the expiry date printed on the packaging.

Disposal Instructions

Expired or unused capsules must be disposed of according to local regulations. Regulators generally advise against flushing medicine down a sink or toilet unless the product labeling specifically permits this. If no drug take-back program is available, the product should be prepared for safe household trash disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oristal found in:

A-Z Index: